Gene-Editing Improves Vision in Blind Rats
Gene-editing techniques like CRISPR/Cas9 can successfully replace faulty genes, and scientists have been exploring their therapeutic potential. But insertion of new genes has generally been limited to dividing cells, like those in the skin and gut, because the techniques depend on processes that are only active during cell division. Most of the body’s cells, however, are non-dividing, including those in the eye, brain, and heart.
To address this limitation, a group of researchers led by Dr. Juan Carlos Izpisua Belmonte at the Salk Institute for Biological Studies in San Diego set out to develop a more versatile approach. Their goal was to develop a technique that could insert new genes even into cells that weren’t dividing. The research was funded in part by NIH’s National Heart, Lung, and Blood Institute (NHLBI). Results were published in Nature on December 1, 2016.
The researchers focused on a DNA-repair mechanism called NHEJ (non-homologous end-joining). NHEJ repairs DNA breaks by rejoining broken DNA ends. It’s active in both dividing and non-dividing cells. This makes it a useful partner to the CRISPR/Cas9 gene-editing tool, which can snip out DNA pieces at precise locations.
The scientists tailored the NHEJ machinery for use along with CRISPR/Cas9. They named the new approach HITI (homology-independent targeted integration). With HITI, a gene is targeted using CRISPR/Cas9 and replaced by a new gene using the cell’s routine NHEJ repair mechanism.
To test the approach in non-dividing cells, the researchers used a harmless virus to deliver the specialized HITI package into a sample of neurons. This led to site-specific insertion of the new gene into these neurons. The team next tested the HITI-enabled gene insertion method in non-dividing cells in mice. They were able to incorporate the new gene into the brain, muscle, kidney, heart, and liver of adult mice.
The scientists next explored whether HITI might be used as a gene-replacement tool to treat disease. They tested a rat model of retinitis pigmentosa, an inherited eye disorder that causes retinal degeneration and eventual blindness in humans.
The team used HITI to replace the mutated Mertk gene that causes blindness in these rats with a functional copy of the gene. The functional gene became incorporated into the rat genome. After 4 weeks, MERTK protein expression was observed in the retina. Light-sensitive eye tests showed improved responses, indicating a partial rescue of vision.
Although the researchers chose to use the CRISPR/Cas9 tool along with HITI in this study, other gene-editing techniques could also be coupled with HITI to insert new genes into the genome.
“We now have a technology that allows us to modify the DNA of non-dividing cells, to fix broken genes in the brain, heart, and liver,” Izpisua Belmonte says. “It allows us, for the first time, to be able to dream of curing diseases that we couldn’t before, which is exciting.”
Story from the National Institutes of Health. Original piece written by Anita Ramanathan. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Wu, J., Greely, H. T., Jaenisch, R., Nakauchi, H., Rossant, J., & Belmonte, J. C. I. (2016). Stem cells and interspecies chimaeras. Nature, 540(7631), 51–59. doi:10.1038/nature20573
How Well Do Cancer Drugs Hit Their Targets? Here’s How to Find OutNews
Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells the drug fails to reach.READ MORE
Solving Protein Puzzle Helps to Design New Cancer DrugsNews
Researchers at Oregon State University have solved a longstanding puzzle concerning the design of molecular motors, paving the way toward new cancer therapies.READ MORE